ESLA
Estrella Immunopharma, Inc.
$1.13
-0.88%
$48.6M
No data for this timeframe.
Vol
Market Cap$48.6M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$908.5K
Inst. Activity3 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$2.6K
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001844417·Prev Close $1.14
Recent Activity
Oct 7, 2025
Insider
Xu Jiandong bought 1,000 shares
Chief Financial Officer @ $1.33 ($1.3K)
Sep 22, 2025
Insider
Xu Jiandong bought 1,000 shares
Chief Financial Officer @ $1.16 ($1.2K)
Sep 11, 2025
Insider
Xu Jiandong bought 100 shares
Chief Financial Officer @ $1.04 ($104.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
122,468 shares ($191.1K)
Inst.
MORGAN STANLEY — NEW
11,097 shares ($17.3K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 (Feb 2026)
Current $1.15
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 9, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 28, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-0.39 | $-0.39 — $-0.39 | -11% YoY | 1 |
| Next FY | $-0.32 ▲ +17.9% | $-0.32 — $-0.32 | 18% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $700.1K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $191.1K | DOUBLED |
| MORGAN STANLEY | $17.3K | NEW |
| BANK OF AMERICA CORP | $16.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 7, 2025 | Xu Jiandong | BUY | $1.3K |
| Sep 22, 2025 | Xu Jiandong | BUY | $1.2K |
| Sep 11, 2025 | Xu Jiandong | BUY | $104.00 |
4 institutional holders with $908.5K total value (582,340 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 448,765 | $700.1K | 77.1% | ADD +48.4% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 122,468 | $191.1K | 21.0% | DOUBLED +1045.7% |
| 3 | MORGAN STANLEY | 11,097 | $17.3K | 1.9% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 10 | $16.00 | 0.0% | DOUBLED +400.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,689 | 122,468 | +1045.7% | $191.1K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 11,097 | — | $17.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 2 | 10 | +400.0% | $16.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 282,843 | 419,711 | +48.4% | $499.5K | 2025-Q3 |
| UBS Group AG | TRIM | 72,773 | 50,347 | -30.8% | $57.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 10,689 | — | $12.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 92 | 2 | -97.8% | $2.00 | 2025-Q3 |
| UBS Group AG | ADD | 41,034 | 72,773 | +77.3% | $69.9K | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 21,684 | 277,578 | +1180.1% | $257.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 91,599 | — | $84.9K | 2025-Q1 |
| UBS Group AG | TRIM | 65,167 | 41,034 | -37.0% | $38.0K | 2025-Q1 |
| UBS Group AG | DOUBLED | 6,523 | 65,167 | +899.0% | $78.2K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 14,531 | 0 | -100.0% | $0.00 | 2024-Q4 |
1 unique insiders with 3 transactions. Net insider value: $2.6K ($2.6K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | Xu Jiandong | Chief Financial Officer | BUY | 1,000 | $1.33 | $1.3K |
| Sep 22, 2025 | Xu Jiandong | Chief Financial Officer | BUY | 1,000 | $1.16 | $1.2K |
| Sep 11, 2025 | Xu Jiandong | Chief Financial Officer | BUY | 100 | $1.04 | $104.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 mean target (Feb 2026)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.15 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-0.39 | $-0.39 | $-0.39 | -11.4% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.32 | $-0.32 | $-0.32 | 18.0% | +17.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.